Table 3.
Cardiometabolic outcomes (change from baseline to 6-year follow-up and mean difference) in the intervention and control group of the LIFEstyle and RADIEL study
| Cardiometabolic outcomes | LIFEstyle study | RADIEL study | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| n | Intervention | n | Control | MDb | BCa 99% | n | Intervention | n | Control | MDb,c | BCa 99% | |
| Δa | Δa | C.I. | Δa | Δa | C.I. | |||||||
| Weight, kg—mean (SD) | 50 | −3.4 (14.2) | 60 | −1.5 (13.5) | −1.8 | −8.8 to 4.7 | 22 | 2.9 (15.4) | 17 | −1.8 (9.3) | 2.0 | −10 to 11.8 |
| BMI, kg/m2—mean (SD) | 50 | –0.5 (5.1) | 60 | 0.0 (4.7) | –0.6 | –2.7 to 1.6 | 22 | 1.1 (5.6) | 17 | –0.6 (3.2) | 0.7 | −3.5 to 4.2 |
| Waist Circumference, cm—mean (SD) | 48 | –0.5 (12.5) | 60 | –0.3 (13.5) | –0.8 | –6.1 to 4.6 | 21 | 7.1 (12.9) | 17 | 8.1 (10.0) | –3.2 | –14.3 to 8.0 |
| Hip Circumference, cm—mean (SD) | 49 | –2.6 (9.9) | 60 | –2.5 (9.4) | –0.5 | –5.0 to 3.6 | 21 | 2.9 (13.1) | 17 | –3.2 (6.6) | 4.8 | –4.6 to 13.8 |
| Systolic Blood pressure, mmHg—mean (SD) | 48 | –3.9 (14.6) | 60 | –6.0 (15.3) | –0.2 | –7.3 to 6.9 | 22 | 2.7 (11.1) | 17 | 3.7 (15.0) | 1.6 | –11.2 to 17.5 |
| Diastolic Blood pressure, mmHg—mean (SD) | 48 | 1.6 (10.2) | 60 | 0.5 (9.4) | –0.5 | –5.1 to 4.4 | 22 | –0.8 (8.4) | 17 | –2.8 (11.0) | 4.1 | –4.1 to 12.4 |
| Fasting glucose, mmol/L—mean (SD) | 36 | 0.0 (0.6) | 52 | 0.0 (1.1) | –0.3 | –0.7 to 0.2 | 22 | –0.1 (0.7) | 17 | 0.0 (0.5) | –0.2 | –0.7 to 0.4 |
| HOMA-IR—mean (SD) | 35 | –0.1 (2.3) | 50 | 0 (2.6) | –0.4 | –1.6 to 0.9 | 18 | 1.4 (2.8) | 16 | 0.8 (2.2) | 0.3 | –2.3 to 2.6 |
| Total Cholesterol, mmol/L—mean (SD) | 36 | –0.1 (1.0) | 52 | 0.0 (0.8) | 0.0 | –0.5 to 0.5 | 22 | –0.1 (0.7) | 16 | –0.1 (0.6) | –0.1 | –0.6 to 0.5 |
| LDL Cholesterol, mmol/L—mean (SD) | 36 | –0.2 (1.0) | 52 | –0.2 (0.7) | 0.0 | –0.4 to 0.4 | 22 | 0.0 (0.7) | 16 | 0.2 (0.5) | –0.2 | –0.8 to 0.4 |
| HDL Cholesterol, mmol/L—mean (SD) | 36 | 0.2 (0.3) | 52 | 0.1 (0.3) | 0.1 | –0.0 to 0.3 | 22 | 0.1 (0.4) | 16 | 0.0 (0.4) | 0.1 | –0.2 to 0.5 |
| Triglycerides, mmol/L—mean (SD) | 36 | –0.3 (1.6) | 52 | –0.1 (0.6) | –0.3 | –0.7 to 0.3 | 22 | –0.1 (0.7) | 16 | 0.1 (0.6) | –0.1 | –0.6 to 0.4 |
| HS-CRP, mg/l—mean (SD) | 36 | 0.1 (4.5) | 52 | 1.8 (5.6) | –1.6 | –4.4 to 1.2 | 22 | –0.5 (6.3) | 17 | –0.1 (2.5) | 0.6 | –3.5 to 5.9 |
| HbA1c, mmol/mol—mean (SD)d | 42 | n.a. | 52 | n.a. | –1.7 | –5.2 to 1.2 | 18 | 1.6 (4.7) | 11 | –0.3 (5.7) | 1.2 | –3.3 to 7.1 |
| Fat percentage, %e | 50 | n.a. | 60 | n.a. | –0.5 | –2.7 to 1.3 | 17 | n.a. | 16 | n.a. | –1.1 | –8.5 to 5.8 |
| PWV, m/sf | 37 | n.a. | 49 | n.a. | 0.1 | –1.2 to 1.1 | 19 | n.a. | 16 | n.a. | 0.4 | –0.8 to 1.7 |
a
Change between baseline and follow-up.
b
Mean differences between intervention and control group at follow-up based on linear regression models adjusted for baseline values, unless stated otherwise.
c
Adjusted for age at baseline.
d
No baseline value in LIFEstyle study, mean difference is unadjusted.
e
No baseline value, mean difference is adjusted for BMI at baseline.
f
No baseline value, mean difference is adjusted for pulse pressure at baseline.